Kornimate/medical-research-clean huggingface dataset:
transcutaneous auricular vagus nerve stimulation treatment on meniere disease

Conditions: Meniere Disease

Summary: objective: to evaluate the effect of transcutaneous auricular vagus nerve stimulation for the patients meniere disease. methods: we accrued 25 patients at beijing tongren hospital. all treatments were self-administered by the patients at home after training at the hospital. patients completed questionnaires at baseline and after 4 weeks, 8 weeks, 12 weeks. tinnitus handicap inventory (thi), dizziness handicap inventory (dhi), pure tone audiometry, visual scale of ear stuffiness and sf-36 were performed to evaluate the therapeutic effects. a difference of p \< 0.05 was considered statistically significant.


Eligibility criteria:
inclusion criteria: 1. age \>=18 and age \<=70. 2. clinical diagnosis of meniere disease. exclusion criteria: 1. history of depression, tumors, thyroid disease, diabetes, cardiac diseases. 2. history of otorhinolaryngology surgery. 3. pregnant or lactating women.

Keywords: transcutaneous auricular vagus nerve stimulation
evaluation of the relationship between air bubbles depth and pregnancy rate in icsi cycles

Conditions: Good Ovarian Response; Infertility History

Summary: the aim of this work is to assess the effect of air bubbles localization inside the uterus on embryo transfer outcome in icsi cycles. is there a relationship between embryo transfer outcome and the distance between fundal endometrial surface and air bubbles assessed by trans-abdominal ultrasound?

all et will be performed on day 3 after oocyte retrieval at the blastocyst stage by one operator under trans-abdominal us guidance performed by one physician, without any anesthesia or sedation with moderate bladder filling. two embryos will be transferred using the same type of catheter which is labotect embryo transfer catheter. it's a semirigid catheter that's less likely to induce endometrial trauma and uterine contractions. the tip of the inner catheter will be placed approximately 1.5-2 cm from the fundal endometrial surface.the distance between the fundal endometrial surface and air bubbles will be measured and categorized as: * group 1: air bubbles depth \<10 mm. * group 2: air bubbles depth \>10 mm. the primary outcome will be biochemical pregnancy rate based on serum quantitative beta-hcg level at 14 days after et. secondary outcome will be clinical pregnancy rate using trans-vaginal us examination at 6 - 8 weeks of amenorrhea to detect the presence of fetal sac \& pulsation.

Eligibility criteria:
inclusion criteria: * women in reproductive period (age 18-38 years). * infertility due to bilateral tubal block or unexplained infertility programmed for icsi. * bmi \< 25 kg/m². * fsh level on cycle day 3 of \< 12 miu/ml exclusion criteria: * previous failed icsi or ivf attempts. * infertility due to male factors. * presence of an abnormal uterine cavity due to endometrial polyps, myomas distorting the uterine cavity, mullerian malformations, endometrial synechiae, etc. (assessed by transvaginal us and/or hysterography). * patients with hydrosalpinx or pyosalpinx. * patients undergoing et after cryopreservation. * patients with blood present on the catheter during the transfer procedure. * patients with difficult transfer or with suspicion of touching the fundus. * poor responders.

Keywords: icsi embryo transfer air bubbles depth
a study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (itp)

Conditions: Primary Immune Thrombocytopenia

Summary: the purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.


Eligibility criteria:
inclusion criteria: * study participant completed tp0003 \[nct04200456\] or tp0006 \[nct04224688\] until visit 27 (week 25) and, in the opinion of the investigator, has been compliant with the tp0003 or tp0006 study assessments * the study participant is considered reliable and capable of adhering to the protocol, visit schedule, or medication intake according to the judgment of the investigator * study participants may be male or female: 1. a male participant must agree to use contraception during the treatment period and for at least 3 months after the final dose of study treatment and refrain from donating sperm during this period 2. a female participant is eligible to participate if she is not pregnant as confirmed by a negative urine pregnancy test and not planning to get pregnant during the participation in the study, not breastfeeding, and at least one of the following conditions applies: not a woman of childbearing potential (wocbp) or a wocbp who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the final dose of study treatment exclusion criteria: * study participant has any ongoing investigational medicinal product (imp)-related serious adverse event (sae) or ongoing severe imp-related treatment-emergent adverse event (teae) experienced during tp0003 or tp0006 * study participant has, at last available assessment of tp0003 or tp0006, 3.0x upper limit of normal (uln) of any of the following: alanine aminotransferase (alt), aspartate aminotransferase (ast), or alkaline phosphatase (alp)

Keywords: itp ucb7665 rozanolixizumab primary immune thrombocytopenia
efficacy and safety of intradermal rn1001 (avotermin) in elderly subjects.

Conditions: Cicatrix

Summary: an exploratory phase-ii trial with intradermal rn1001 (avotermin) to investigate scar prevention and reduction and acceleration of healing. the trial has an additional objective to evaluate several different scar assessment techniques that can be used in future clinical trials in the prevention and reduction of scarring.

double blind, randomised, placebo and standard care controlled, single centre study. each subject receives a total of 6 wounds, two incisions and four punch biopsies. each subject serves as their own control, i.e. arm 1 incisions/biopsies randomly received one of two treatments and arm 2 incisions/biopsies received the same treatments as for arm 1 but in reverse. the randomisation of the treatment allowed for control of possible positional effects on healing/scarring. healed scars from incisional wounds excised from arm 1 and arm 2 after 6 months for histological analysis.

Eligibility criteria:
inclusion criteria: * clinically healthy, male and female subjects aged 60 years and over. all females will be at least 2 years post menopausal. * weight between 50 and 150kg or a body mass index within the permitted range for their height using quetelet's index-weight (kg)/height²(m). the permitted index is between 15 - 35 kg/m2. exclusion criteria: * subjects who on direct questioning and physical examination have a history or evidence of hypertrophic or keloid scarring or with tattoos or previous scars in the area to be biopsied. * subjects with a personal history of a bleeding disorder. * subjects with a skin disorder that is chronic or currently active and which the investigator considers will adversely affect the healing the acute wounds or involves the areas to be examined in this trial. * subjects with any clinically significant medical condition that would impair wound healing including renal, hepatic, haematological, neurological or immune disease. * subjects with a history of clinically significant drug hypersensitivity to lignocaine or allergy to surgical dressings to be used in this trial. * subjects with any clinically significant abnormality following review of pre trial laboratory data and physical examination (see above). * subjects who are taking, or have taken, any investigational drugs, long term oral, topical or inhaled corticosteroid therapy, hormone replacement therapy (hrt) or anti-coagulant drugs in the thirty days prior to day 0. * subjects who have evidence of drug abuse. * subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis b surface antigen or hepatitis c antibody. subjects with previous vaccination against hepatitis b are not excluded per se. * subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis b core antibody and who show less than 10 units per litre of anti-hbs. * subjects who have previously had a positive result to the test for hiv antibodies, or who admit to belonging to a high-risk group. * in the opinion of the investigator, a subject who is not likely to complete the trial for what ever reason.
dental age estimation by different methods in patients with cleft lip and palate

Conditions: Dental Age Estimation; Cleft Lip and Palate

Summary: the aim of this study is to investigate whether there is a significant difference in dental age between children with clp and healthy controls using the willems method, cameriere european formula and london atlas. it is aimed to create a new formula if there is a significant difference in dental age between children with clp and healthy controls.

dental age is widely evaluated by pedodontists, forensic dentists and orthodontists. while a delay in tooth development may be associated with growth retardation and learning difficulties, dental age determination can also be used for forensic age determination for children whose birth information is uncertain. a clear assessment of maturation in children with continued growth is important in establishing a dental treatment plan. there are two basic approaches to dental age determination in children: evaluation of eruption of teeth in the oral cavity, evaluation of the development and mineralization of crowns and roots on dental radiographs. in many methods, the developmental stages of different numbers of permanent teeth are used. the most commonly used method for determining dental age in children; is the demirjian method that evaluates the development of seven left permanent mandibular teeth in eight stages (from a to h). willems et al. in 2001, they modified the demirjian method by conducting a study on the fact that it showed higher age determination in the belgian caucasian population. the adapted method was named the willems method. it is stated that one of the advantages of this method is that it is a relatively simple system for determining tooth age. one of the most widely used methods of dental age determination recently is the european formula of cameriere et al., which is calculated based on open apex. it has been reported that this method has been tested on different population groups, and the results are accurate and reliable. an atlas method was proposed by a group of london researchers in 2010. the atlas shows all the teeth array images of certain age groups as a schematic series. age determination is made by deciding which reference image matches the individual's panoramic radiography image more.

Eligibility criteria:
inclusion criteria: * 5-14 years old * healthy children * children with clp * patients without missing left mandibular permanent teeth on panoramic radiography exclusion criteria: * children younger than 5 years old and older than 14 years (children that cannot be assessed by the willems and cameriere method) * poor quality panoramic radiography * patients who have received orthodontic treatment * patients who received restorative or endodontic treatment

Keywords: children dental age estimation cleft lip and palate chronological age london atlas cameriere european formula willems method
aspects of vulnerability of people living with hiv in the alpine arc region

Conditions: HIV Infections

Summary: hiv infection in france has become a chronic disease and treatment has allowed patients to increase their life expectancy. however, these promising results suffer from a very large variability within the socio-epidemiological subgroups, and life expectancy at 20 years of age is still one third lower than in the general population. few studies of metropolitan cohorts investigated precariousness as an independent risk factor for mortality. the investigators chose to consider the vulnerability of people living with hiv (plwha) through the measurement of a validated french quantitative score, called epices ("évaluation de la précarité et des inégalités de santé dans les centres d'examens de santé ", evaluation of precariousness and health inequalities in health examination centers).

hiv infection in france has become a chronic disease and treatment has allowed patients to increase their life expectancy. however, these promising results suffer from a very large variability within the socio-epidemiological subgroups, and life expectancy at 20 years of age is still one third lower than in the general population. few studies of metropolitan cohorts investigated precariousness as an independent risk factor for mortality. the investigators chose to consider the vulnerability of people living with hiv (plwha) through the measurement of a validated french quantitative score, called epices (evaluation of precariousness and health inequalities in health examination centers). using a self-administered questionnaire administered during an annual follow-up visit to an infectious disease specialist, the investigators seek to define in the alpine arc region in france, socio-demographic data associated with greater precariousness among plwha.

Eligibility criteria:
inclusion criteria: * any person living with hiv presenting for consultation with their infectious disease referrer. * patient followed for at least 6 months for their hiv infection * patient with undetectable or detectable hiv viral load * patient of legal age at the time of the study * patient informed of the study and having expressed no objection to the collection of health data exclusion criteria: * patient opposed or unable to express opposition to participation in the study * patient is a minor at the time of the study * patient taking antiretroviral therapy for less than 6 months
oral mucosal lesions among smokers in an egyptian population.

Conditions: Smokers

Summary: this cross-sectional study will assess the prevalence of oral changes among smokers in an egyptian cohort (patients attending to the hospital of faculty of dentistry - cairo university), aiming that this study can serve as a baseline for future studies with the goal of finding ways to improve oral health and increase awareness of the hazards of smoking in egypt

the participants will be selected from the pool of the clinics of oral medicine, periodontology and diagnosis department and the diagnostic center, faculty of dentistry - cairo university. for each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.

Eligibility criteria:
inclusion criteria: * gender: males and females. * age: all age groups. * smokers. * individuals who agreed to sign the informed consent. exclusion criteria: * individuals suffering from any systemic disease. * individuals on medications. * non-egyptians.
the use of 5mg finasteride versus 200mg spironolactone and topical 5% minoxidil in treating postmenopausal female androgenetic alopecia

Conditions: Female Androgenetic Alopecia

Summary: the investigators propose to conduct a head-to-head, randomized clinical trial to compare the effectiveness of minoxidil with spironolactone and finasteride in treating postmenopausal females with androgenetic alopecia (aga).

participants diagnosed with aga will be randomized into one of the two treatment arms outlined below, and will take the assigned treatment for a total duration of 12 months. medications will be dispensed by a nurse who is blinded to the participants within each treatment group. global photograph assessment and participant questionnaires at 0, 4, 8 and 12 months will be the primary means to determine improvement in hair loss. compare the following interventions in treating postmenopausal female aga: a) combination 5% minoxidil and 200mg spironolactone (combination group) b) 5mg finasteride with placebo topical preparation (single group)

Eligibility criteria:
inclusion criteria: * female * postmenopausal (\>60 years old or with total hysterectomy) * diagnosed with androgenetic alopecia * no chemical processing or changes in hair products throughout the study exclusion criteria: * men * premenopausal women (\<60 or without hysterectomy) * participants allergic to any of the study medications (minoxidil, finasteride, spironolactone) * participants with other co-existing forms of alopecia (traction, alopecia areata, or scarring alopecias) * participants with obstructive uropathy or advanced liver disease * prior hair loss treatment within the last 6 months * hair loss from the chemotherapy or other medication-induced alopecia * hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a period.

Keywords: hair loss post menopausal
managing distress in malignant brain cancer

Conditions: Cancer Metastatic to Brain; Brain Metastases, Adult

Summary: to identify potential adaptations of the managing cancer and living meaningfully (calm) intervention that will be required for service members, veterans, their beneficiaries, and civilian cancer metastasis to the brain (bmet) populations.

single-arm, mixed-methods, phase iia, proof-of-concept trial to inform calm adaptations for service members (sms), veterans, their beneficiaries, and civilians with bmet.

Eligibility criteria:
inclusion criteria: * diagnosis of brain metastasis (bmet) confirmed via medical records, radiography or histopathology * at least 2 weeks post-surgical cranial resection or cranial biopsy (if applicable) * score \> 20 on the tics * report elevated depression (phq-9 score ≥ 10) or death anxiety symptoms (dadds score ≥ 15) * ability to read, speak, and understand english * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * major communication difficulties, which would prohibit psychotherapeutic interaction * inability to meet with interventionist via an electronic device for telehealth intervention sessions * inability to understand and provide informed consent * medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk

Keywords: bmet calm service members veterans
take charge of your diabetes

Conditions: Diabetes; Hypertension

Summary: the investigator plans to assess enrollment rates among two different enrollment methods, while providing a behavioral economic intervention to enhance the uptake of home-health monitoring devices to lower hemoglobin a1c among patients with uncontrolled diabetes. the study is focusing on enrollment methods since the standard randomized control trial only reaches 15% of the population. the study is seeking to understand the effectiveness of a behavioral intervention, when rolled out in a larger population.


Eligibility criteria:
inclusion criteria: 1. adults between 18 and 80 years of age 2. primary care patients at the division of general internal medicine clinics at the university of pennsylvania 3. hemoglobin a1c measured within the last 8 weeks greater than 8.0% or no measured hemoglobin a1c measured in the last two years 4. a confirmed diabetes diagnosis 5. planning to stay in area for study duration (6 months) 6. can understand and communicate fluently in english exclusion criteria: 1. unable to read and give consent 2. suffer from an uncontrolled psychiatric disease

Keywords: diabetes enrollment methods behavioral economic intervention opt-in enrollment opt-out enrollment lottery financial incentives
the effects of multi-strain probiotics in adults with diarrhea predominant irritable bowel syndrome

Conditions: Diarrhea Predominant Irritable Bowel Syndrome

Summary: the investigators will evaluate the efficacy of multi-strain probiotics in adults with diarrhea predominant irritable bowel syndrome.


Eligibility criteria:
inclusion criteria: * willing to consent/undergo necessary procedures * between the age of 19 and 75 years * diarrhea predominant irritable bowel syndrome (satisfied with rome ii criteria) exclusion criteria: * uncontrolled hypertension (blood pressure \> 180/110 mmhg) * uncontrolled diabetes mellitus (fbs \> 200 mg/dl) * malignancy, cerebrovascular disease, cardiovascular disease * history of abdominal surgery except appendectomy and hernia repair * inflammatory bowel disease * clinically or laboratory-confirmed gastroenteritis * the use of motility drug or dietary fiber supplement in 2 weeks * serum cr \> 2 x upper normal limit * ast or alt \> 2 x upper normal limit * pregnancy, lactating woman
enalapril maleate and doxorubicin hydrochloride in treating women with breast cancer

Conditions: Breast Cancer

Summary: rationale: drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. enalapril maleate may help protect heart cells from the side effects of chemotherapy. it is not yet known whether giving enalapril maleate before or after doxorubicin hydrochloride is more effective in treating women with breast cancer. purpose: this randomized clinical trial is studying giving enalapril maleate together with doxorubicin hydrochloride to see how well it works in treating women with breast cancer.

this study is a drug interaction study designed to study the effects of enalapril on doxorubicin metabolism. women with breast cancer for whom at least two cycles every 14 day doxorubicin is planned will be considered for enrollment. study participation will be for 2 treatment cycles of doxorubicin or approximately 4 weeks. patients will receive a 14 day course of daily enalapril in association with one cycle of doxorubicin and receive no study agent during the other cycle allowing patients to act as their own control. the sequence of enalapril dosing will be assigned by randomization at study enrollment. blood samples for pharmacokinetics will be drawn before and at 7 time points after each of the two doses of doxorubicin. for each patient, serum doxorubicin and doxorubicinol concentrations both on and off of enalapril will be compared.

Eligibility criteria:
inclusion criteria: * tissue diagnosis of a breast carcinoma * the oncologist must have prescribed doxorubicin as part of the planned chemotherapy regimen * have acceptable organ function within 14 days of enrollment defined as: * liver function: total bilirubin, ast and alt within normal institutional limits * kidney function: estimated creatinine clearance \> 60 ml/min calculated creatinine clearance (for females) - formula: (140 - age) x weight x .85 divided by (scr x 72) * at least 18 years old * patient must have given written informed consent indicating an understanding of the investigational nature of the study * agrees not to consume grapefruit juice while on the study exclusion criteria: * known allergy to enalapril * taking any known p450 cytochrome inducers or inhibitors * taking any herbal supplements while on the study or the week prior to receiving doxorubicin * taking an ace-inhibitor or angiotensin receptor blocker * pregnant or lactating. enalapril is pregnancy categories c (first trimester) and d (second and third trimesters)

Keywords: stage i breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer